Breath takeout gives Zambon lung transplant candidate, U.S. foothold

Italian pharma Zambon is acquiring Sofinnova Partners portfolio company Breath Therapeutics for €140 million ($156 million) up front to expand its respiratory pipeline and establish a foothold in the U.S.

Shareholders of Breath Therapeutics B.V. (Munich, Germany) are also eligible for up to €360 million ($401 million) in milestones...